AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31759771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simo decoction 20 ml q8h for 24 h
Number of subjects: 224
Study 31759771 — intervention group
Group type: COMPARATOR
Intervention: Domperidone suspension 20 mg/20 ml q6h for 24 h
Number of subjects: 224
Study 31394599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 0
Study 31394599 — intervention group
Group type: COMPARATOR
Intervention: Sham chamber sessions
Number of subjects: 0
Study 31394599 — intervention group
Group type: COMPARATOR
Intervention: Normative controls
Number of subjects: 0
Study 28870647 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac bone plus plasma rich in growth factors (PRGF)
Number of subjects: 32
Study 28870647 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried bone allograft (FDBA) plus plasma rich in growth factors (PRGF)
Number of subjects: 32
Study 25180554 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged in smoking used cigarettes
Number of subjects: 244
Study 24476469 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea consumption (3 cups per day for 7 days)
Number of subjects: 20
Study 24476469 — intervention group
Group type: COMPARATOR
Intervention: Hot water consumption (control)
Number of subjects: 20
Study 24476469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia-reperfusion protocol after tea consumption
Number of subjects: 20
Study 23036544 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer-I test in Behçet's disease patients
Number of subjects: 89
Study 23036544 — intervention group
Group type: COMPARATOR
Intervention: Schirmer-I test in control group
Number of subjects: 89
Study 23036544 — intervention group
Group type: EXPERIMENTAL
Intervention: Break-up time (BUT) test in Behçet's disease patients
Number of subjects: 89
Study 23036544 — intervention group
Group type: COMPARATOR
Intervention: Break-up time (BUT) test in control group
Number of subjects: 89
Study 23036544 — intervention group
Group type: EXPERIMENTAL
Intervention: Impression cytology score in Behçet's disease patients
Number of subjects: 89
Study 23036544 — intervention group
Group type: COMPARATOR
Intervention: Impression cytology score in control group
Number of subjects: 89
Study 19581631 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-dose efavirenz (200 mg/d on days 1-6, 400 mg/d on days 7-13, 600 mg/d from day 14)
Number of subjects: 114
Study 19581631 — intervention group
Group type: COMPARATOR
Intervention: Full-dose efavirenz (600 mg/d from day 1)
Number of subjects: 114
Study 19581631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Stepped-dose and Full-dose)
Number of subjects: 114
Study 17472846 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated polyacrylonitrile membrane (AN69ST)
Number of subjects: 33
Study 17472846 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation with calcium-containing dialysate (RCA-Ca3.0)
Number of subjects: 33
Study 17472846 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation with calcium-free dialysate (RCA-Ca0)
Number of subjects: 33
Study 17472846 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 33
Study 16126025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 654
Study 16126025 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 654
Study 12468607 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 263
Study 12468607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 9796234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal response task
Number of subjects: 0
Study 9796234 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual word response task
Number of subjects: 0
Study 7648641 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis during perioperation
Number of subjects: 525
Study 7648641 — intervention group
Group type: COMPARATOR
Intervention: Routine use of antibiotics as usual (Control)
Number of subjects: 525
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide dinitrate (ISDN)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg isosorbide dinitrate (ISDN)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (ISDN)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ISDN + 25 mg gallopamil (G)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ISDN + 50 mg gallopamil (G)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ISDN + 80 mg propranolol (P)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ISDN + 25 mg gallopamil (G)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ISDN + 50 mg gallopamil (G)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ISDN + 80 mg propranolol (P)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN + 25 mg gallopamil (G)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN + 50 mg gallopamil (G)
Number of subjects: 18
Study 2686258 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN + 80 mg propranolol (P)
Number of subjects: 18
Study 7388119 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pyridoxine per day
Number of subjects: 0
Study 7388119 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg pyridoxine per day
Number of subjects: 0
Study 7388119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g pyridoxine per day
Number of subjects: 0
Study 7388119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30665392 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity physical activity (MVPA)
Number of subjects: 1252
Study 30665392 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 1252
Study 30665392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting time
Number of subjects: 1252
Study 30665392 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing time
Number of subjects: 1252
Study 30665392 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA and sitting time by sex
Number of subjects: 1252
Study 27913066 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone‐17‐valerate cream
Number of subjects: 202
Study 27913066 — intervention group
Group type: COMPARATOR
Intervention: Essex® cream (moisturizer)
Number of subjects: 202
Study 25338266 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based after-school program (experimental group, n = 25), attended two times a week.
Number of subjects: 54
Study 25338266 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 29), did not participate in an after-school program.
Number of subjects: 54
Study 24402587 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day synthetic osmotic dilators
Number of subjects: 72
Study 24402587 — intervention group
Group type: COMPARATOR
Intervention: Overnight Laminaria
Number of subjects: 72
Study 22676330 — intervention group
Group type: EXPERIMENTAL
Intervention: FREMS and topical treatment (Group A)
Number of subjects: 20
Study 22676330 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment alone (Group B)
Number of subjects: 20
Study 20393636 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine fumarate
Number of subjects: 0
Study 18778138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy treatment for alcohol dependence
Number of subjects: 57
Study 18778138 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence goal
Number of subjects: 57
Study 18778138 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled drinking goal
Number of subjects: 57
Study 18778138 — intervention group
Group type: COMPARATOR
Intervention: Traditional measures of outcome
Number of subjects: 57
Study 15641125 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 mg/day increasing to 20 mg/day)
Number of subjects: 30
Study 15641125 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25 mg/day increasing to 100 mg/day)
Number of subjects: 30
Study 15641125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11991367 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 18
Study 11991367 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 18
Study 9915366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) 50 microg bolus injection followed by continuous infusion of 302 microg per day
Number of subjects: 17
Study 7768573 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 8
Study 2333596 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of the nail edge and chemical ablation of germinal matrix edge with 70% aqueous phenol (Group A)
Number of subjects: 66
Study 2333596 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision of nail edges and germinal matrix edges (Group B)
Number of subjects: 66
Study 7035598 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of stilboestrol and ethisterone therapy during pregnancy
Number of subjects: 136
Study 7035598 — intervention group
Group type: COMPARATOR
Intervention: Inactive tablet (control)
Number of subjects: 136
Study 30227765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention designed to decrease cardiometabolic risk factors in women
Number of subjects: 0
Study 30227765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored guided imagery intervention
Number of subjects: 0
Study 30227765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful physical activity intervention (yoga)
Number of subjects: 0
Study 28470821 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 12
Study 28470821 — intervention group
Group type: COMPARATOR
Intervention: Institutionalization
Number of subjects: 12
Study 25928298 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted marketing messages
Number of subjects: 0
Study 25928298 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical information
Number of subjects: 0
Study 23578678 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR)
Number of subjects: 40
Study 23578678 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 40
Study 23578678 — intervention group
Group type: COMPARATOR
Intervention: Lower dose CTP (80 mAs)
Number of subjects: 40
Study 23578678 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose CTP (100 mAs)
Number of subjects: 40
Study 23578678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IR and FBP algorithms
Number of subjects: 40
Study 23578678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both algorithms
Number of subjects: 40
Study 21250993 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 34
Study 21250993 — intervention group
Group type: COMPARATOR
Intervention: Control condition (placebo)
Number of subjects: 34
Study 19967603 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot/cold water immersion
Number of subjects: 20
Study 19967603 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 20
Study 19967603 — intervention group
Group type: COMPARATOR
Intervention: No recovery (control)
Number of subjects: 20
Study 17896734 — intervention group
Group type: EXPERIMENTAL
Intervention: Posters in paediatricians' waiting area during intervention week
Number of subjects: 808
Study 17896734 — intervention group
Group type: COMPARATOR
Intervention: No posters in paediatricians' waiting area during control week
Number of subjects: 808
Study 17896734 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (posters)
Number of subjects: 808
Study 14749224 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (33% of energy)
Number of subjects: 53
Study 14749224 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (18% of energy)
Number of subjects: 53
Study 11337737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical abdominal wall lift (AWL)
Number of subjects: 0
Study 11337737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AWL with low-pressure pneumoperitoneum (3 to 4 mm Hg)
Number of subjects: 0
Study 11337737 — intervention group
Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum (12 mm Hg)
Number of subjects: 0
Study 9429053 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) at a dose of 60 U.kg‐1 BW three times a week and oral iron treatment (ferrofumarate)
Number of subjects: 32
Study 9429053 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) and oral iron treatment
Number of subjects: 32
Study 9429053 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐administered subcutaneous recombinant human erythropoietin (rhEPO)
Number of subjects: 32
Study 7939760 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg/m2 given as a single dose over 1 hour
Number of subjects: 56
Study 7939760 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg/m2 given in divided hourly daily doses for 3 days
Number of subjects: 56
Study 7939760 — intervention group
Group type: COMPARATOR
Intervention: Both schedules of paclitaxel
Number of subjects: 56
Study 3282004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 3282004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 0
Study 31983186 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer educational program
Number of subjects: 154
Study 31983186 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 29117275 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT alone
Number of subjects: 704
Study 29117275 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT+ISG
Number of subjects: 704
Study 29117275 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 704
Study 27149404 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge core biopsy needle
Number of subjects: 56
Study 27149404 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge core biopsy needle
Number of subjects: 56
Study 26214630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by conformal 3-dimensional (3D) radiotherapy (RT)
Number of subjects: 85
Study 26214630 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy with cisplatin and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy with carboplatin and etoposide
Number of subjects: 85
Study 23439617 — intervention group
Group type: EXPERIMENTAL
Intervention: State-of-the-art methodology for clinical trials
Number of subjects: 0
Study 23439617 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous approach to menstrual trial data collection
Number of subjects: 0
Study 19880208 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training combined with antioxidant supplementation
Number of subjects: 0
Study 19880208 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 0
Study 19011437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 20
Study 19011437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 40 mg
Number of subjects: 20
Study 19011437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 80 mg
Number of subjects: 20
Study 19011437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 20
Study 19011437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15834341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford Cobbometer
Number of subjects: 24
Study 12430112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micro g added to 0.5% hyperbaric ropivacaine 18 mg
Number of subjects: 59
Study 12430112 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.2 mL added to 0.5% hyperbaric ropivacaine 18 mg
Number of subjects: 59
Study 10355002 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR: 2.0‐3.0)
Number of subjects: 4500
Study 10355002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid (30-325 mg/day) plus dipyridamole (400 mg daily)
Number of subjects: 4500
Study 10355002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid only (30-325 mg/day)
Number of subjects: 4500
Study 8942891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive subconjunctival mitomycin C (MMC)
Number of subjects: 174
Study 8942891 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive mitomycin C (Control)
Number of subjects: 174
Study 1760462 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 12
Study 1760462 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training and graded neck exercises (RGP)
Number of subjects: 12
Study 7036396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible endoscopic sclerotherapy using 5% sodium morrhuate
Number of subjects: 13
Study 7036396 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal transection/reanastomosis employing the EEA Auto Suture stapling instrument
Number of subjects: 13
Study 7036396 — intervention group
Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 13
Study 31780589 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically-supervised gradual reduction of antipsychotic medication leading to discontinuation when possible
Number of subjects: 134
Study 31780589 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment with antipsychotic medication
Number of subjects: 134
Study 31780589 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically-supervised gradual reduction of antipsychotic medication
Number of subjects: 134
Study 29392287 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive keratograph breakup time (NIKBUT)
Number of subjects: 74
Study 29392287 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein breakup time (TBUT)
Number of subjects: 74
Study 29392287 — intervention group
Group type: EXPERIMENTAL
Intervention: NIKBUT
Number of subjects: 74
Study 29392287 — intervention group
Group type: COMPARATOR
Intervention: TBUT
Number of subjects: 74
Study 27684802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) at 4.33 μg/kg combined with sufentanil (SUF) at 3.0 μg/kg via PCIA
Number of subjects: 25
Study 23839729 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased training volume from 4.9 to 18 h.wk-1
Number of subjects: 6
Study 23839729 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased training volume
Number of subjects: 6
Study 22497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine extended-release (LTG XR)
Number of subjects: 0
Study 22497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic ITT (P‐ITT) methodology
Number of subjects: 0
Study 22497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF) methodology
Number of subjects: 0
Study 19439743 — intervention group
Group type: EXPERIMENTAL
Intervention: Scorpion-specific F(ab')(2) antivenom
Number of subjects: 15
Study 19439743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17069546 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 17069546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12582834 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (alpha(1)-adrenergic antagonist), single oral dose
Number of subjects: 0
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy based on the Berlin‐Frankfurt‐Münster 76/79 study
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intensification (DI)
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance intrathecal methotrexate
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: One vs no DI phase for lower risk patients
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vs one DI phase for intermediate risk patients
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: CCG 'augmented regimen' for higher risk patients with a slow day 7 marrow response
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone in place of prednisone in induction and maintenance
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone in DI
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year EFS
Number of subjects: 16000
Study 11187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-year cumulative rates of isolated CNS relapses
Number of subjects: 16000
Study 8797480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CBG)
Number of subjects: 44
Study 8797480 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (BCR)
Number of subjects: 44
Study 1625101 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO, 400 IU/kg three times a week plus iron, 20 mg/wk intravenously
Number of subjects: 22
Study 1625101 — intervention group
Group type: COMPARATOR
Intervention: No rHuEPO and no iron
Number of subjects: 22
Study 6387184 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim (20 patients)
Number of subjects: 40
Study 6387184 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 patients)
Number of subjects: 40
Study 31733760 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity hatha yoga exercises (HIY)
Number of subjects: 44